TAPP Submits Comments to USITC on TRIPS Waiver Expansion

TAPP recently submitted comments to the U.S. International Trade Commission to express concerns with a possible expansion of the TRIPS waiver beyond COVID-19 vaccines.

The TRIPS waiver has already set a dangerous precedent that has hindered intellectual property and patent rights for medical innovators, and its continuance would be a serious problem for American innovators and patients.

TAPP recognizes that strong intellectual property protections are essential for medical innovators and for the research and development into new cures and medicines.

TAPP calls on USITC to stop the expansion of the TRIPS waiver and instead focus on protecting and bolstering American medical innovators.

Read our full comments here.